Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EV71-CA16 bivalent hand-foot-mouth disease vaccine
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The EV71-CA16 bivalent hand-foot-mouth disease vaccine is a prophylactic vaccine candidate developed by AIM Vaccine Co. to prevent hand-foot-mouth disease (HFMD). It is an inactivated vaccine designed to provide broad protection against the two primary causative agents of HFMD: Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16). While monovalent EV71 vaccines are currently available and effective against EV71-related HFMD, they do not offer cross-protection against CA16, which is a major contributor to the disease burden and often co-circulates during outbreaks. This bivalent formulation aims to address this gap by inducing neutralizing antibodies against both viral serotypes. As of 2024, the candidate is in the preclinical development stage.
- Other names
- EV71-CA16二价手足口病疫苗EV71-CA16 bivalent vaccineEV-71-CA16 bivalent vaccineEV 71-CA16 bivalent vaccinebivalent hand-foot-mouth disease vaccine
02
Targets
Enterovirus A71 capsid proteinCoxsackievirus A16 capsid protein (CVA16 capsid)
Beyond the preview
Go deeper on EV71-CA16 bivalent hand-foot-mouth disease vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EV71-CA16 bivalent hand-foot-mouth disease vaccine.